| Year |
Citation |
Score |
| 2018 |
Wei L, Omata M, Lim YS, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-Oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, et al. HCV phylogenetic Signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research. PMID 30120954 DOI: 10.1016/J.Antiviral.2018.08.001 |
0.468 |
|
| 2018 |
Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, et al. No Impact of Resistance Associated Substitutions on the Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir for 12 Weeks in HCV DAA-experienced Patients. Journal of Hepatology. PMID 30098373 DOI: 10.1016/J.Jhep.2018.07.023 |
0.476 |
|
| 2017 |
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, et al. Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies. Journal of Hepatology. PMID 29221887 DOI: 10.1016/J.Jhep.2017.11.032 |
0.492 |
|
| 2017 |
Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology. 514: 134-141. PMID 29175627 DOI: 10.1016/J.Virol.2017.11.003 |
0.435 |
|
| 2017 |
Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antiviral Therapy. PMID 28650844 DOI: 10.3851/Imp3181 |
0.43 |
|
| 2017 |
Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, et al. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 28369210 DOI: 10.1093/Cid/Cix260 |
0.54 |
|
| 2017 |
Xu S, Doehle B, Rajyaguru S, Han B, Barauskas O, Feng J, Perry J, Dvory-Sobol H, Svarovskaia ES, Miller MD, Mo H. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6. Antiviral Therapy. PMID 28248189 DOI: 10.3851/Imp3149 |
0.484 |
|
| 2017 |
Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, et al. NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome. Journal of Hepatology. PMID 28108232 DOI: 10.1016/J.Jhep.2017.01.007 |
0.489 |
|
| 2017 |
Wyles D, Thompson A, Lawitz E, Willems B, Gane EJ, Svarovskaia E, Dvory-Sobol H, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo HM, Asselah T, et al. POSTER PRESENTATIONS: Posters Thursday, 20 April 2017: Viral hepatitis: Hepatitis C – Clinical (therapy)THU-257 - No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)30924-8 |
0.385 |
|
| 2017 |
Sarrazin C, Cooper CL, Manns MP, Reddy RK, Kowdley K, Dvory-Sobol H, Svarovskia E, Martin R, Doehle BP, Camus G, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, et al. No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)30915-7 |
0.306 |
|
| 2017 |
Reddy KR, Cooper CL, Manns M, Kowdley KV, Spellman J, Llewellyn J, Dvory-Sobol H, Svarovskaia E, Martin R, Doehle BP, Camus G, Stamm L, Hyland RH, Brainard D, Mo H, et al. No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies Gastroenterology. 152. DOI: 10.1016/S0016-5085(17)33587-4 |
0.306 |
|
| 2016 |
Shah SR, Chowdhury A, Mehta R, Kapoor D, Duseja A, Koshy A, Shukla A, Sood A, Madan K, Sud R, Nijhawan S, Pawan R, Prasad M, Kersey K, Jiang D, ... ... Doehle B, et al. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India. Journal of Viral Hepatitis. PMID 27933698 DOI: 10.1111/Jvh.12654 |
0.472 |
|
| 2016 |
Lawitz EJ, Dvory-Sobol H, Doehle B, Worth A, McNally J, Brainard DM, Link JO, Miller MD, Mo H. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrobial Agents and Chemotherapy. PMID 27353271 DOI: 10.1128/Aac.00763-16 |
0.467 |
|
| 2016 |
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir. Gastroenterology. PMID 27296509 DOI: 10.1053/J.Gastro.2016.06.002 |
0.489 |
|
| 2016 |
Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia ES, De-Oertel S, Knox S, Brainard DM, Miller MD, Mo H, Sakamoto N, Takehara T, Omata M. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. Journal of Viral Hepatitis. PMID 27196675 DOI: 10.1111/Jvh.12549 |
0.505 |
|
| 2016 |
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, et al. In Vitro Antiviral Activity and Resistance Profile Characterization of the HCV NS5A Inhibitor Ledipasvir. Antimicrobial Agents and Chemotherapy. PMID 26824950 DOI: 10.1128/Aac.02524-15 |
0.446 |
|
| 2016 |
Kulkarni AS, Damha MJ, Schinazi RF, Mo H, Doehle B, Sagan SM, Götte M. A complex network of interactions between S282 and G283 of HCV NS5B and the template strand affect susceptibility to Sofosbuvir and Ribavirin. Antimicrobial Agents and Chemotherapy. PMID 26824949 DOI: 10.1128/Aac.02436-15 |
0.385 |
|
| 2016 |
Charlton M, Manns M, Dvory-Sobol H, Svarovskaia E, Doehle B, Arterburn S, Yun C, Brainard DM, Mchutchison JG, Miller MD, Mo H, Afdhal N, Mutimer D. Resistance Analyses for Ledipasvir/Sofosbuvir Containing Regimens in Patients Infected with Chronic HCV who Have Advanced Liver Disease or are Post Liver Transplant (Solar-1 & 2 Studies) Journal of Hepatology. 64. DOI: 10.1016/S0168-8278(16)01701-3 |
0.384 |
|
| 2016 |
Hezode C, Reau N, Svarovskaia E, Doehle BP, Chodavarapu K, Dvory-Sobol H, Mcnally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts S, O’leary JG. Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies Journal of Hepatology. 64. DOI: 10.1016/S0168-8278(16)00629-2 |
0.473 |
|
| 2016 |
Wyles D, Brau N, Kottilil S, Daar E, Workowski K, Luetkemeyer A, Adeyemi O, Ruane P, Doehle B, Huang Kc, Osinusi A, McNally J, Brainard D, McHutchison J, Naggie S, et al. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study Journal of Hepatology. 64. DOI: 10.1016/S0168-8278(16)00129-X |
0.489 |
|
| 2015 |
Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions. The Journal of Infectious Diseases. PMID 26603202 DOI: 10.1093/Infdis/Jiv564 |
0.381 |
|
| 2015 |
Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. The New England Journal of Medicine. PMID 26569658 DOI: 10.1056/Nejmoa1512614 |
0.486 |
|
| 2015 |
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, et al. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Annals of Internal Medicine. PMID 26551263 DOI: 10.7326/M15-1014 |
0.47 |
|
| 2015 |
Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Annals of Internal Medicine. PMID 26551051 DOI: 10.7326/M15-1000 |
0.432 |
|
| 2015 |
Simon TG, Kim AY, Stamm LM, Liu L, Mo H, Doehle B, Pang PS, Brainard DM, McHutchison JG, Gustafson J, Lauer GM, Chung RT. The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antiviral Therapy. PMID 26440471 DOI: 10.3851/Imp2997 |
0.466 |
|
| 2015 |
Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D, Doehle B, Knox SJ, Massetto B, McHutchison JG, Esmat G. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Journal of Hepatology. PMID 25937436 DOI: 10.1016/J.Jhep.2015.04.023 |
0.49 |
|
| 2015 |
Pol S, Sulkowski MS, Hassanein T, Gane EJ, Liu L, Mo H, Doehle B, Kanwar B, Brainard D, Subramanian GM, Symonds WT, McHutchison JG, Nahass RG, Bennett M, Jacobson IM. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology (Baltimore, Md.). 62: 129-34. PMID 25847509 DOI: 10.1002/Hep.27836 |
0.447 |
|
| 2015 |
Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). The Lancet. Infectious Diseases. 15: 397-404. PMID 25773757 DOI: 10.1016/S1473-3099(15)70050-2 |
0.473 |
|
| 2015 |
Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. Journal of Hepatology. 62: 1040-6. PMID 25450208 DOI: 10.1016/J.Jhep.2014.10.044 |
0.473 |
|
| 2015 |
Hedskog C, Doehle B, Chodavarapu K, Gontcharova V, Crespo Garcia J, De Knegt R, Drenth JP, McHutchison JG, Brainard D, Stamm LM, Miller MD, Svarovskaia E, Mo H. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (Baltimore, Md.). 61: 471-80. PMID 25099344 DOI: 10.1002/Hep.27361 |
0.463 |
|
| 2015 |
Doehle BP, Svarovskaia ES, Chodavarapu K, McNally J, Pianko S, Roberts SK, Brainard DM, Miller MD, Mo H. P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)31096-5 |
0.473 |
|
| 2015 |
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Martin R, Zeuzem S, Lawitz E, Hyland R, Pang PS, Knox S, Gane E, Reddy R, Afdhal N, Mizokami M, Omata M, et al. P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30976-4 |
0.42 |
|
| 2014 |
Ruane PJ, Ain D, Meshrekey R, Riad J, Soliman M, Mikhail S, Wolfe PR, Kersey K, Doehle B, Jiang D, Symonds WT. P1243 Sofosbuvir Plus Ribavirin, An Interferon-Free Regimen, In The Treatment Of Treatment-Naive And Treatment-Experienced Patients With Chronic Genotype 4 Hcv Infection Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)61403-3 |
0.437 |
|
| 2014 |
Hedsko C, Doehle B, Chodavarapu K, Gontcharova V, Brainard D, Symonds WT, Miller MD, Svarovskaia E, Mo H. P229 Hcv Genotype 2 And 1 Inter-Genotype Recombination Variants Account For Discordance Between Lipa-Based Hcv Genotyping And Ns5B Sequencing Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)60391-3 |
0.421 |
|
| 2014 |
Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass R, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, Symonds WT, McHutchison JG, Morgan T, Chung RT. O111 Safety And Efficacy Of Treatment With The Interferon-Free, Ribavirin-Free Combination Of Sofosbuvir + Gs-5816 For 12 Weeks In Treatment Naive Patients With Genotype 1–6 Hcv Infection Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)60113-6 |
0.437 |
|
| 2014 |
Esteban R, Nyberg L, Lalezari J, Ni L, Doehle B, Kanwar B, Brainard D, Subramanian M, Symonds WT, McHutchison JG, Rodriquez-Torres M, Zeuzem S. O8 Successful Retreatment With Sofosbuvir-Containing Regimens For Hcv Genotype 2 Or 3 Infected Patients Who Failed Prior Sofosbuvir Plus Ribavirin Therapy Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)60010-6 |
0.448 |
|
| 2014 |
Nyberg LM, Lalezari J, Ni L, Doehle B, Kanwar B, Brainard DM, Subramanian GM, Symonds WT, McHutchison JG, Rodriguez-Torres M. 239 Successful Retreatment With Sofosbuvir-Containing Regimens for HCV Genotype 2 or 3 Infected Patients Who Failed Prior Sofosbuvir Plus Ribavirin Therapy Gastroenterology. 146. DOI: 10.1016/S0016-5085(14)63290-X |
0.473 |
|
| 2013 |
Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M. IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. Plos Pathogens. 9: e1003330. PMID 23633957 DOI: 10.1371/Journal.Ppat.1003330 |
0.387 |
|
| 2013 |
Rustagi A, Doehle BP, McElrath MJ, Gale M. Two new monoclonal antibodies for biochemical and flow cytometric analyses of human interferon regulatory factor-3 activation, turnover, and depletion. Methods (San Diego, Calif.). 59: 225-32. PMID 22705311 DOI: 10.1016/J.Ymeth.2012.05.011 |
0.342 |
|
| 2012 |
Doehle BP, Chang K, Fleming L, McNevin J, Hladik F, McElrath MJ, Gale M. Vpu-deficient HIV strains stimulate innate immune signaling responses in target cells. Journal of Virology. 86: 8499-506. PMID 22647704 DOI: 10.1128/Jvi.00424-12 |
0.388 |
|
| 2012 |
Doehle BP, Chang K, Rustagi A, McNevin J, McElrath MJ, Gale M. Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. Journal of Virology. 86: 8367-74. PMID 22593165 DOI: 10.1128/Jvi.00423-12 |
0.39 |
|
| 2010 |
Doehle BP, Chang K, Jr. MG. SS4-5 Viral regulation of a TLR/RLR-independent program of host cell recognition of HIV-1 infection Cytokine. 52: 43. DOI: 10.1016/J.Cyto.2010.07.180 |
0.371 |
|
| 2009 |
Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. Journal of Virology. 83: 10395-405. PMID 19706707 DOI: 10.1128/Jvi.00849-09 |
0.439 |
|
| 2008 |
Doehle B, Gale M. 244 HIV-1 antagonizes innate antiviral signaling pathways by targeting interferon regulatory factor-3 (IRF-3) Cytokine. 43: 297-298. DOI: 10.1016/J.Cyto.2008.07.309 |
0.342 |
|
| 2007 |
Bogerd HP, Wiegand HL, Doehle BP, Cullen BR. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology. 364: 486-93. PMID 17434555 DOI: 10.1016/J.Virol.2007.03.019 |
0.555 |
|
| 2006 |
Doehle BP, Bogerd HP, Wiegand HL, Jouvenet N, Bieniasz PD, Hunter E, Cullen BR. The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. Journal of Virology. 80: 12102-8. PMID 17035335 DOI: 10.1128/Jvi.01600-06 |
0.528 |
|
| 2006 |
Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Research. 34: 89-95. PMID 16407327 DOI: 10.1093/Nar/Gkj416 |
0.528 |
|
| 2005 |
Doehle BP, Schäfer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology. 339: 281-8. PMID 15993456 DOI: 10.1016/J.Virol.2005.06.005 |
0.557 |
|
| 2005 |
Doehle BP, Schäfer A, Wiegand HL, Bogerd HP, Cullen BR. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. Journal of Virology. 79: 8201-7. PMID 15956565 DOI: 10.1128/Jvi.79.13.8201-8207.2005 |
0.574 |
|
| 2005 |
Yi R, Doehle BP, Qin Y, Macara IG, Cullen BR. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. Rna (New York, N.Y.). 11: 220-6. PMID 15613540 DOI: 10.1261/Rna.7233305 |
0.561 |
|
| 2004 |
Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. The Embo Journal. 23: 2451-8. PMID 15152192 DOI: 10.1038/Sj.Emboj.7600246 |
0.559 |
|
| 2004 |
Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceedings of the National Academy of Sciences of the United States of America. 101: 3770-4. PMID 14999100 DOI: 10.1073/Pnas.0307713101 |
0.563 |
|
| Show low-probability matches. |